BO-1055, a novel DNA cross-linking agent with remarkable low myelotoxicity shows potent activity in sarcoma models

DNA damaging agents cause rapid shrinkage of tumors and form the basis of chemotherapy for sarcomas despite significant toxicities. Drugs having superior efficacy and wider therapeutic windows are needed to improve patient outcomes. We used cell proliferation and apoptosis assays in sarcoma cell lin...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncotarget
Autors principals: Ambati, Srikanth R., Shieh, Jae-Hung, Pera, Benet, Lopes, Eloisi Caldas, Chaudhry, Anisha, Wong, Elissa W.P., Saxena, Ashish, Su, Tsann-Long, Moore, Malcolm A.S.
Format: Artigo
Idioma:Inglês
Publicat: Impact Journals LLC 2016
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5190008/
https://ncbi.nlm.nih.gov/pubmed/27248664
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.9657
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars